The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of afatinib alone and in combination with dasatinib in triple-negative breast cancer cell lines.
Mohamed F.K. Ibrahim
No relevant relationships to disclose
Alexandra Canonici
Research Funding - Boehringer Ingelheim
Denis Collins
No relevant relationships to disclose
John Crown
Research Funding - Boehringer Ingelheim
Other Remuneration - Bristol-Myers Squibb
Norma O'Donovan
Research Funding - Boehringer Ingelheim